PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPramlintide
Pramlintide
Symlin (pramlintide) is a protein pharmaceutical. Pramlintide was first approved as Symlin on 2005-03-16. It is used to treat type 1 diabetes mellitus and type 2 diabetes mellitus in the USA. It is known to target calcitonin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Symlin (discontinued: Symlin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pramlintide acetate
Tradename
Company
Number
Date
Products
SYMLINAstraZenecaN-021332 RX2007-09-25
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
symlinpenNew Drug Application2019-12-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
type 1 diabetes mellitusEFO_0001359D003922E10
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BX: Other blood glucose lowering drugs, excl. insulins in atc
— A10BX05: Pramlintide
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E1078651438
Diabetes mellitusD003920HP_0000819E08-E13510661034
Type 2 diabetes mellitusD003924EFO_0001360E11—323311
Body weightD001835EFO_0004338——6—1—7
HyperglycemiaD006943HP_0003074R73.9———123
Weight gainD015430HP_0004324————2—2
HypoglycemiaD007003HP_0001943E16.2———1—1
Weight lossD015431HP_0001824————1—1
SchizophreniaD012559EFO_0000692F20———1—1
Psychotic disordersD011618—F20.81———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9—91—110
Prediabetic stateD011236EFO_1001121R73.03—11——1
Glucose intoleranceD018149HP_0000833R73.03—11——1
Appetite regulationD001069———11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OverweightD050177—E66.3—4———4
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F031————1
Cognitive dysfunctionD060825HP_0001268G31.841————1
CarcinomaD002277—C80.01————1
Squamous cell carcinomaD002294——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43————11
Migraine without auraD020326EFO_0005296G43.0————11
Metabolic diseasesD008659EFO_0000589E88.9————11
Metabolic bone diseasesD001851HP_0000938—————11
Bone diseasesD001847—M89.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePramlintide
INNpramlintide
Description
PRAMLINTIDE
Classification
Protein
Drug classpeptides: amylin derivatives or mimics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O
Identifiers
PDB—
CAS-ID151126-32-8
RxCUI—
ChEMBL IDCHEMBL2103758
ChEBI ID—
PubChem CID16132446
DrugBankDB01278
UNII IDD3FM8FA78T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CALCR
CALCR
Organism
Homo sapiens
Gene name
CALCR
Gene synonyms
NCBI Gene ID
799
Protein name
calcitonin receptor
Protein synonyms
Uniprot ID
Q6T712
Mouse ortholog
Calcr (12311)
calcitonin receptor (Q8CAB0)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Symlin – Amylin Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Symlin – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Pramlintide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,492 documents
View more details
Safety
Black-box Warning
Black-box warning for: Symlinpen
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,874 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use